Neurogene to Participate in Stifel 2026 Virtual CNS Forum
Neurogene (Nasdaq: NGNE) management will participate in the Stifel 2026 Virtual CNS Forum in a fireside chat on Wednesday, March 18 at 9:00 a.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Format: Management will participate in a fireside chat
Date: Wednesday, March 18 at 9:00 a.m. ET
A live webcast of the fireside chat will be accessible from the Investor Relations section of Neurogene’s website under events, where a replay of the event will also be available for a limited time.
About Neurogene
Neurogene (NASDAQ: NGNE) is a clinical-stage biotechnology company focused on developing life-changing genetic medicines for people and their families impacted by devastating neurological diseases. The Company is using a biology-first approach paired with optimized delivery to develop purpose-built genetic medicines, including programs powered by its novel and proprietary EXACT™ transgene regulation technology. Neurogene is advancing its lead gene therapy program,
View source version on businesswire.com: https://www.businesswire.com/news/home/20260311342818/en/
Company Contact:
Mike Devine
Executive Director, Corporate Communications
michael.devine@neurogene.com
Investor Contact:
Argot Partners
Neurogene@argotpartners.com
Source: Neurogene Inc.